A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.

scientific article published on October 2010

A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/1535-7163.MCT-10-0197
P698PubMed publication ID20889729

P50authorEssam GhazalyQ58283215
P2093author name stringSimon Joel
Thomas Powles
Jackie Perry
Christiana Kitromilidou
Eva H McGrowder
P2860cites workMultidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)Q33194199
P433issue12
P921main subjectchemotherapyQ974135
P304page(s)3322-3329
P577publication date2010-10-01
P1433published inMolecular Cancer TherapeuticsQ2363144
P1476titleA synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP
P478volume9

Reverse relations

cites work (P2860)
Q35171274ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors
Q37958162Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Q35720625Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up
Q38936104Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review
Q30313117Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity
Q38735063In vitro and in vivo evaluation of paclitaxel-lapatinib-loaded F127 pluronic micelles.
Q35708124Interaction of innovative small molecule drugs used for cancer therapy with drug transporters
Q38035056Lung cancer stem cells: tumor biology and clinical implications
Q47111415NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells
Q34440220Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
Q33600072Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
Q35284749Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation
Q35946822Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance

Search more.